

# Asia Pacific Journal of Clinical Medical Research

Editor-in-Chief:

**Assoc. Prof. Danying Liao**

*Tongji Medical College, Huazhong University of Science and Technology, China*

Copyright © 2025. ASIA PACIFIC SCIENCE PUBLICATIONS  
COMPANY LIMITED. Complimentary Copy.

## Asia Pacific Journal of Clinical Medical Research

*Asia Pacific Journal of Clinical Medical Research (APJCMR)* is an international, peer-reviewed, open access journal dedicated to advancing clinical medical research across multiple disciplines. The journal serves as a platform for publishing high-quality original research, reviews, and clinical studies that enhance the understanding of medical practices, treatment innovations, and healthcare outcomes, thereby supporting patient care and medical advancements in the Asia Pacific region and beyond. It covers mainly but not limits to the following areas:

- Advancements in Clinical Practice and Patient Care
- Evidence-Based Medicine
- Healthcare Outcomes and Treatment Efficacy
- Patient Safety and Harm Reduction
- Medical Ethics and Clinical Decision-Making
- Clinical Trials and Medical Interventions
- Healthcare Policy and Management
- Public Health and Preventive Medicine
- Medical Education and Training
- Innovations in Medical Technologies
- Special Medical Fields and Rare Diseases
- Healthcare Systems and Organizational Studies

### About Publisher:

Asia Pacific Science Press (APSP) is a swiftly expanding publisher of peer-reviewed and open-access journals, strategically located in Hong Kong. As a reliable and esteemed corporation, APSP is dedicated to promoting and serving a wide array of subject areas, ultimately contributing to the betterment of humanity. By disseminating knowledge to a global community of scholars, practitioners, researchers, and students, we strive to establish ourselves as the world's leading independent academic and professional publisher.

Submission instructions: You can submit your manuscript through the official website ([www.apspublisher.com](http://www.apspublisher.com)) or email ([editor.chst@apspublisher.com](mailto:editor.chst@apspublisher.com)). All manuscripts will go through a rapid peer review and production, making the process of publishing simpler and more efficient.

### Publisher Headquarter

Room 03, 7th Floor, Block B, Tuen Mun Industrial Centre, 2 New Ping Street, Tuen Mun, Hong Kong, China  
Website : [www.apspublisher.com](http://www.apspublisher.com)  
Email : [www.apspublisher.com](mailto:www.apspublisher.com)

### Fujian Province Office, China

603-1, 6th Floor, Building B20, Chengyi North Street, Software Park, Jimei District, Xiamen City, Fujian Province, China  
Website : <https://ojs.apspublisher.com/index.php/amit>  
Email : [amit@apspublisher.com](mailto:amit@apspublisher.com)

## Table of Contents

- 1 Clinical Analysis of Adverse Reactions Associated with the Use of Anticancer Chemotherapy Drugs**  
*Zhao Lu*
- 5 Study on the Application and Time-Dependent Effects of Antibiotics in the Treatment of Neonatal Pneumonia**  
*Zhao Lu*



# Clinical Analysis of Adverse Reactions Associated with the Use of Anticancer Chemotherapy Drugs

Zhao Lu\*

The Fifth Clinical School of Capital Medical University, Beijing, 100000, China

\*Corresponding author: Zhao Lu, luzhao@mail.ccmu.edu.cn

**Copyright:** 2025 Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC 4.0), permitting distribution and reproduction in any medium, provided the original author and source are credited, and explicitly prohibiting its use for commercial purposes.

**Abstract: Objective:** To investigate the various adverse reactions observed in cancer patients undergoing chemotherapy and provide a basis for developing rational chemotherapy regimens. **Methods:** A retrospective study was conducted on 180 cancer patients treated between August 2014 and August 2016. All patients received chemotherapy, and the adverse reactions occurring during treatment were analyzed. **Results:** The types of adverse reactions in cancer patients after chemotherapy varied, but digestive system-related adverse reactions were more common, including nausea, hair loss, and diarrhea. In this study, the age distribution of the 180 cancer patients was analyzed. The results showed that 56 patients were aged 13–29 years, 72 patients aged 30–47 years, and 52 patients aged 48–67 years. **Conclusion:** Cancer patients undergoing chemotherapy have a high probability of experiencing adverse reactions, which can cause significant discomfort. In such cases, targeted interventions must be implemented to manage treatment-related adverse reactions and prevent their occurrence.

**Keywords:** Tumor Chemotherapy; Drug Application; Adverse Reaction

**Published:** Dec 31, 2025

**DOI:** <https://doi.org/10.62177/apjcmr.v1i6.1015>

## Introduction

Cancer is a common disease with a high mortality rate. Currently, chemotherapy is the primary treatment method in clinical practice. Chemotherapy can exert its therapeutic effect by killing tumor cells in the patient's body. However, due to its lack of targeting, chemotherapy also damages healthy cells, leading to a series of adverse reactions and causing significant harm to the patient's body. To investigate the adverse reactions experienced by cancer patients following chemotherapy, this study focuses on patients with tumors admitted to our hospital. We analyze the adverse reactions that occur after the administration of chemotherapy drugs in clinical practice and explore specific intervention measures, as detailed below.

## 1. Materials and Methods

### 1.1 General Data

The study included 88 male patients and 92 female patients. The age range of the patients was 13–69 years, with an average age of  $44.82 \pm 3.82$  years. Tumors were located in the breast in 32 patients, in the stomach in 38 patients, in the uterus in 20 patients, in the lungs and bronchi in 44 patients, and in other parts of the body in 46 patients.

### 1.2 Methods

Collected basic data from all 180 tumor patients, investigated and statistically analyzed chemotherapy-related data, including

patient age, gender, initial chemotherapy regimen, chemotherapy duration, chemotherapy drugs, and adverse reactions<sup>[1]</sup>. Summarized and calculated the above data, analyzed the adverse reactions of tumor chemotherapy drugs and their influencing factors, and adjusted the chemotherapy drug regimens accordingly<sup>[2]</sup>.

### 1.3 Observation indicators

Common adverse reactions observed during the use of anticancer chemotherapy drugs serve as observation indicators, including nausea, diarrhea, hair loss, neurotoxicity, and hand-foot syndrome, etc.<sup>[3]</sup>.

## 2. Results

### 2.1 Age Distribution

An age distribution analysis was conducted on the 180 tumor patients in this study. The results showed that 56 patients were aged 13–29 years, 72 patients were aged 30–47 years, and 52 patients were aged 48–69 years.

### 2.2 Analysis of Adverse Reaction Manifestations

This study conducted a systematic review and analysis of drug-related adverse reactions during treatment in 180 patients with malignant tumors. Through the integration of clinical data, peripheral neurotoxicity was found to have the highest incidence rate in this group, with a cumulative total of 86 cases, accounting for 47.78% of the total cases. This figure is significantly higher than the values reported in the literature for traditional chemotherapy regimens. This result may be associated with the use of platinum-based drugs, such as oxaliplatin, and other neurotoxic chemotherapy regimens in the treatment of these patients. This complication not only directly affects treatment adherence but may also have a persistent impact on long-term quality of life<sup>[4]</sup>.

The digestive system is one of the common sites of adverse reactions following chemotherapy in cancer patients. Research data indicate that 37.78% of 68 cases experienced vomiting as an adverse reaction, a pathological phenomenon associated with multiple pathophysiological processes such as 5-hydroxytryptamine receptor activation and blood-brain barrier permeability. Additionally, survey data indicate that the incidence of hand-foot syndrome has significantly increased, accounting for 36.67% of cases, involving 66 patients. This phenomenon is often attributed to the use of specific chemotherapy drugs such as anti-angiogenic targeted therapies and capecitabine, which can cause severe skin and mucosal damage, significantly increasing the risk of treatment interruption. There were 28 cases of diarrhea, accounting for 15.56%. Although hair loss is a typical side effect of cytotoxic drugs, only 8 cases were observed in this study, representing 4.44%, which is likely due to the limited use of taxane-based drugs in this patient population. The data are summarized in Table 1.

*Table 1: Incidence rates of adverse reactions to chemotherapy in cancer patients (total number of patients: 180)*

Type of adverse reaction	Number of Cases (Cases)	Incidence Rate
Nausea	6	37.78
Diarrhea	2	15.56
Hair loss	8	4.44
Hand-foot syndrome	66	36.67
Peripheral neurotoxicity	86	47.78

Chemotherapy, as one of the key modalities in comprehensive cancer treatment, has seen drug toxicity reactions emerge as critical factors constraining treatment efficacy and patient quality of life<sup>[5]</sup>. A systematic review of chemotherapy data from 180 cancer patients between August 2014 and August 2016 was conducted to comprehensively elucidate the diagnostic and therapeutic characteristics of various adverse reactions induced by major anticancer drugs.

In terms of toxic characteristics in the digestive system, there are significant differences among various drugs. Antimetabolite drugs exhibit a higher rate of gastrointestinal toxicity (n=117/180), with 79.3% of patients reporting persistent nausea, 34.6% experiencing vomiting of grade III or higher, and 42.7% experiencing diarrhea. This clearly indicates that the adverse effects of this class of drugs are associated with direct damage to the epithelial cells of the gastrointestinal mucosa. The platinum-based drug group (n=100/180) and the antimitotic drug group (n=99/180) had similar proportions and incidence rates. The incidence of oral mucositis in the platinum-based drug group, particularly the delayed-onset nausea symptoms it causes,

warrants clinical attention, with an incidence rate of 21.11%. This involved 180 cases of topoisomerase inhibitors (n=38), with a combined incidence of intestinal dysfunction reaching 63.2%, closely linked to the narrow therapeutic index of the drugs.

Cardiac toxicity signs showed a clear dose-dependent trend in anthracycline drugs. In the doxorubicin group, the rate of left ventricular ejection fraction reduction  $\geq 10\%$  was 23.7%. When the cumulative dose reached 400 mg/m<sup>2</sup> or higher, the risk of cardiac dysfunction sharply increased, with a confidence interval of 1.87–5.43 and a confidence level of 95%. After structural adjustment, doxorubicin remained unchanged, with a 12.9% incidence of subclinical ECG abnormalities, underscoring the need for rigorous cardiac monitoring of novel anthracycline-based drugs.

Analysis of liver toxicity test results showed that the rates of abnormal liver function indicators in the bleomycin group (n=68) and the camptothecin group (n=45) were 39.7% and 57.8%, respectively. Within the first 72 hours of administration, 84.6% of patients in the bleomycin group experienced elevated AST/ALT levels, while the carmopride group exhibited delayed increases in bilirubin levels, with a median time of 8 days. A dynamic liver function monitoring model was established, significantly enhancing clinical warning efficacy. In the mitomycin group (n=32), urinary system adverse reactions were concentrated, with microalbuminuria cases accounting for 70%, and 21.9% of patients progressed to nephrotic syndrome. The primary pathological manifestation of this toxicity is drug-induced tubular injury. After optimizing hydration therapy, the incidence of grade III or higher renal injury significantly decreased from 17.2% to 8.4% (P=0.033). The analysis of paclitaxel hypersensitivity reactions showed that pre-treatment with dexamethasone and histamine antagonists significantly reduced the incidence of severe hypersensitivity reactions, from 6.8% to 1.2% (P < 0.01). Delayed-type skin rashes occurred in 11.3% of cases, indicating the need for personalized immune regulation. The adverse reactions observed in all 108 tumor patients during treatment are shown in Table 2.

*Table 2: Statistics and classification of adverse reactions associated with chemotherapy drugs in cancer patients (total number of patients: 180)*

Drug Category	Adverse Reaction Type	Number of Cases (Examples)	Incidence Rate/Notes
Gastrointestinal System Adverse Reactions			
Platinum-based drugs	Gastrointestinal adverse reactions	10	55.56
Antimicrotubule drugs	Gastrointestinal adverse reactions	99	55.00
Topoisomerase inhibitors	Gastrointestinal adverse reactions	3	21.11
Antimetabolites	Gastrointestinal adverse reactions	1	65.00
Other systemic adverse reactions			
Doxorubicin/Epirubicin	Cardiac injury	-	-
Bleomycin/Carmestine	Liver injury	-	-
Mitomycin	Urinary system adverse reactions	-	-
Paclitaxel	Allergic reactions	-	-

### 3. Discussion

Chemotherapy has been increasingly used in the clinical treatment of cancer patients. It is characterized by rapid onset, high efficacy, high toxicity, and severe adverse reactions. On one hand, it effectively controls the progression of the disease; on the other hand, its poor targeting ability often damages normal tissues, leading to adverse reactions in patients. Therefore, it is essential to accelerate medical technological innovation and improve the standards of cancer chemotherapy to benefit patients more effectively. Additionally, chemotherapy can be combined with surgery to promote patient recovery, improve quality of life, and extend survival. During treatment, it is crucial to have a clear understanding of the adverse reactions caused by chemotherapy, select appropriate anticancer drugs rationally, and minimize toxicity while ensuring therapeutic efficacy.

When using chemotherapy, cancer patients should select the appropriate chemotherapy method based on the type of adverse reactions to alleviate the suffering caused by these reactions. By analyzing the factors causing adverse reactions, it was

found that, first, many anticancer drugs are Western medications, which have complex compositions and are difficult to effectively regulate in terms of quality. Second, many anticancer drugs are composite formulations containing antigens and haptens, which often trigger allergic reactions in patients. Finally, anticancer drugs contain a large number of microparticles that can cause damage when acting on patients, particularly in cases of liver failure, leading to reduced glomerular filtration rate, tubular secretion capacity, and renal blood flow, thereby affecting the absorption of anticancer drugs. If a cancer patient's liver function declines, the reduced blood flow to the liver will decrease the activity of liver enzymes and the liver's detoxification capacity, making it difficult to effectively eliminate the toxicity of anticancer drugs and ultimately leading to adverse reactions. During treatment, it is essential to strengthen the standardized management of reporting adverse reactions associated with the use of anticancer drugs to achieve the goal of effectively preventing and treating adverse reactions and treatment side effects. Additionally, collaborative mechanisms can be established to enhance communication among medical staff, patients, and clinical pharmacists, enabling real-time information exchange to discuss the current status of drug adverse reactions and develop corresponding strategies. In this process, clinical pharmacists play a crucial role in conducting regular surveys and analyses of adverse reactions occurring during the use of anticancer drugs, providing better guidance for subsequent chemotherapy implementation, and thereby improving the efficacy of anticancer chemotherapy.

## **Funding**

No

## **Conflict of Interests**

The authors declare that there is no conflict of interest regarding the publication of this paper.

## **Reference**

- [1] Mao, L. L., Deng, D. D., & Tang, C. X. (2025). Retrospective analysis of adverse drug reactions to anticancer chemotherapy drugs in a certain hospital. *Chinese Prescription Drugs*, 23(9), 70–73.
- [2] Zhang, H., & Zhang, C. (2025). The application value of overall longitudinal strain in echocardiography for assessing cardiac toxicity caused by anticancer chemotherapy drugs. *Imaging Research and Medical Applications*, 9(7), 92–94.
- [3] Yin, G. S. (2024, September 12). Toxic and adverse reactions of anticancer chemotherapy drugs: What you need to know. *Medicine, Health, and Wellness News*, (006).
- [4] Ren, D. J., Zhang, J. L., Liu, M. Y., et al. (2024). Analysis of the rational use of anti-emetic drugs in cancer chemotherapy patients in our hospital. *Chinese Journal of Pharmacy*, 35(12), 1495–1499.
- [5] Xiao, Y. (2024). The "invisible challenges" behind tumor radiotherapy. *Health Essentials*, (24), 18.



# Study on the Application and Time-Dependent Effects of Antibiotics in the Treatment of Neonatal Pneumonia

Zhao Lu\*

The Fifth Clinical School of Capital Medical University, Beijing, 100000, China

\*Corresponding author: Zhao Lu, luzhao@mail.ccmu.edu.cn

**Copyright:** 2025 Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC 4.0), permitting distribution and reproduction in any medium, provided the original author and source are credited, and explicitly prohibiting its use for commercial purposes.

**Abstract:** This article first outlines the fundamental definitions of *Mycoplasma pneumoniae* and the basic principles of antibiotics. It then analyzes and discusses the progress in antibiotic application and time-effect studies for neonatal pneumonia treatment, specifically comparing conventional antibiotic therapy with stepwise treatment regimens, and contrasting monotherapy with penicillin, monotherapy with cephalosporins, and combination therapy. Finally, it offers a prospective outlook on antibiotic application and time-effect research in neonatal pneumonia treatment, aiming to provide valuable reference for further scholarly investigations.

**Keywords:** Neonatal Pneumonia; Antibiotics; Clinical Application; Time-Dependent Effects; Research Progress; Future Outlook

**Published:** Dec 31, 2025

**DOI:** <https://doi.org/10.62177/apjcmr.v1i6.1016>

## Introduction:

Neonatal pneumonia primarily arises when infants inhale amniotic fluid, meconium, or other foreign substances during intrauterine development, delivery, or the postpartum period, leading to pulmonary infection. Additionally, neonatal exposure to pathogenic microorganisms during delivery or neonatal care can also trigger pneumonia. Typically, affected infants exhibit clinical symptoms such as rapid breathing, severe coughing, and fever, which directly compromise the respiratory system. As blood oxygen saturation levels decline, the condition may become life-threatening. Antibiotic therapy is the primary treatment for neonatal pneumonia. Specific antibiotics are used to achieve bactericidal and bacteriostatic effects, preventing the spread of pulmonary inflammation. Once the inflammation is adequately controlled, clinical symptoms like coughing, fever, and rapid breathing subside, thereby ensuring the infant's safety. To understand the current state of clinical research on neonatal pneumonia treatment, this article analyzes and discusses the application of antibiotics in neonatal pneumonia therapy and advances in time-effect studies. It aims to provide valuable references for related research topics. Detailed content is presented below.

## 1. Overview of *Mycoplasma pneumoniae*

*Mycoplasma pneumoniae* is an independent microorganism lacking a cell wall. Commonly used clinical antibiotics such as cephalosporins and penicillins are ineffective against *Mycoplasma pneumoniae* infections. Extensive clinical research indicates that *Mycoplasma pneumoniae* exhibits relatively high susceptibility to quinolone antibiotics with low resistance rates, whereas its susceptibility to macrolides is relatively low with higher resistance rates. However, quinolones may

adversely affect the physical development of infants and young children, precluding their use. Clinically, macrolides are primarily employed for treating neonatal pneumonia. The efficacy of azithromycin, for instance, has gained widespread recognition among physicians, demonstrating macrolides' strong clinical effectiveness against mycoplasma pneumonia<sup>[1]</sup>.

## 2. Fundamental Principles of Antibiotics

Antibiotics refer to metabolic products generated by higher plants and microorganisms during natural survival processes, exhibiting pathogenic resistance or related activities. These substances effectively inhibit the proliferation of specific pathogenic microorganisms, preventing their excessive multiplication and subsequent damage to host cells. Analysis of antibiotic mechanisms reveals that clinical applications inhibit pathogen proliferation through multiple pathways: suppressing nucleic acid transcription and replication, inhibiting protein synthesis, disrupting bacterial cell wall formation, and altering cell membrane permeability. These actions shorten pathogen survival time to achieve therapeutic outcomes.

For instance, two commonly used antibiotics in clinical practice are penicillin and cephalosporin. Penicillin is primarily extracted from *Penicillium* fungi. When used clinically, it effectively disrupts bacterial structural components and inhibits bacterial cell wall synthesis, thereby achieving the desired therapeutic effects of sterilization and inflammation reduction. Cephalosporins are derived from natural cephalosporin C, obtained through the cultivation of *Cephalosporium coronatum*, which undergoes semi-synthetic modification to produce cephalosporins. These drugs exhibit a relatively broad spectrum of antibacterial activity. In clinical applications, cephalosporins also inhibit bacterial growth by disrupting cell wall synthesis<sup>[2]</sup>. Comparing the two classes, penicillins exhibit a relatively higher incidence of allergic reactions in clinical use. However, regardless of the antibiotic chosen, physicians must avoid overuse. Patient misuse of antibiotics may lead to the emergence of drug-resistant bacteria, diminishing the clinical efficacy of both penicillins and cephalosporins and compromising effective disease control.

## 3. Advances in Antibiotic Application and Time-Dependent Effects in Neonatal Pneumonia Treatment

### 3.1 Comparative Study of Conventional Antibiotic Therapy vs. Stepwise Treatment Regimens

In her study<sup>[3]</sup>, Jin Jiani administered conventional antibiotic therapy to the control group and a stepwise antibiotic regimen to the observation group. Comparing key indicators between groups—including overall clinical response rates, symptom resolution, serum parameter changes, and adverse antibiotic treatment incidence—revealed significantly superior recovery outcomes in the observation group ( $P < 0.05$ ).

The study concluded that in treating neonatal pneumonia, stepwise antibiotic therapy allows timely adjustment of antibiotic dosage based on the patient's condition at appropriate stages. This approach achieves optimal therapeutic outcomes—such as shortening recovery time and reducing adverse drug reactions—while maintaining safety and reliability. Analysis of this study demonstrates strict adherence to medical research regulations, obtained informed consent from parents of newborn pneumonia patients, and was conducted under the supervision of the hospital's Medical Ethics Committee. These measures ensured scientific rigor, lending high credibility to the research conclusions.

### 3.2 Comparative Study of Monotherapy with Penicillin, Monotherapy with Cephalosporin, and Combination Therapy

In conducting related research<sup>[4]</sup>, statistically analyzed antibiotic usage in 90 pediatric pneumonia cases, documenting treatment data for ceftriaxone, cefazolin sodium, cefazolin sodium, penicillin, cefuroxime with penicillin, cefazolin sodium with penicillin, and cefazolin with penicillin. The investigation revealed that current neonatal pneumonia treatment primarily involves monotherapy with penicillin, monotherapy with cephalosporins, or combination therapy (penicillin and cephalosporins). Among these, combination therapy was administered to the largest number of patients, followed by monotherapy with penicillin.

Post-treatment analysis revealed that infants receiving combination therapy exhibited the highest incidence of complications. This clearly indicates that due to the immature development of neonatal organs, the combined use of penicillin and cephalosporin drugs poses significant health risks to infants, directly manifested as elevated complication rates. Additionally,

combination therapy is more complex, as physicians must precisely control the ratios and dosages of combined medications to avoid adversely affecting the child's health. Given the higher incidence of complications in children receiving combination therapy, their recovery periods were prolonged, resulting in overall poor clinical outcomes for this regimen.

Comparing data from children treated with either monotherapy penicillin or monotherapy cephalosporin reveals that those receiving penicillin monotherapy achieved clinical recovery in a relatively shorter timeframe than those on cephalosporin monotherapy. This indicates that the clinical efficacy of monotherapy with cephalosporins is inferior to that of monotherapy with penicillin. However, when comparing the two regimens, the incidence of complications was relatively lower in children treated with monotherapy cephalosporins. This indicates that following a multidisciplinary consultation for neonatal pneumonia, if the infant's condition is deemed not severely critical, monotherapy with cephalosporins may be selected to prevent complications. When the infant's condition is relatively severe, clinicians should adopt monotherapy with penicillin to ensure antibiotics rapidly suppress the proliferation of pathogenic microorganisms within the infant's body, preventing deterioration of the condition that could threaten the infant's life.

### **3.3 Comparative Analysis of Antibiotic Application and Time-Effect Research Findings in Neonatal Pneumonia Treatment**

Comparing the findings of Sun Zhicui and Jin Jiani reveals apparent contradictions: Sun's study indicates monotherapy outperforms combination therapy, while Jin's research shows stepwise antibiotic therapy surpasses conventional monotherapy. While these conclusions appear contradictory at first glance, deeper analysis reveals no conflict. Combination therapy involves pairing antibiotics with cephalosporins, whereas stepwise antibiotic therapy allows physicians to dynamically adjust treatment regimens based on real-time monitoring of the infant's condition. This approach ensures more rational antibiotic use and better disease control. Thus, in treating neonatal pneumonia, the optimal approach for antibiotic administration is to adjust the regimen based on the infant's real-time condition changes. This eliminates the negative effects of monotherapy and ensures effective control of the infant's condition.

## **4.Future Research Directions on Antibiotic Application and Time-Dependent Effects in Neonatal Pneumonia Treatment**

Future research in this area should not only delve into the clinical efficacy of antibiotics to identify more effective treatment regimens but also standardize and regulate antibiotic protocols—including dosage and administration procedures. This will enhance the reference value of research findings and facilitate the transfer of relevant experience into clinical practice. Furthermore, to reduce mortality rates in neonatal pneumonia treatment, major hospitals should enhance communication and collaboration. Organizing specialized conferences to share research insights and clinical experience will consolidate medical resources, ensuring optimal care for every case of neonatal pneumonia and safeguarding the health and lives of affected infants.

## **Conclusion**

In summary, this article focuses on antibiotic application and time-effect studies in neonatal pneumonia treatment, discussing current research progress. By examining research findings alongside actual clinical treatment practices, it outlines prospects for future research. Given the unique nature of neonatal pneumonia, the research and outlook presented herein represent only the author's humble perspective. To facilitate more systematic investigation and discussion, a rigorous thematic plan should be organized. This plan should examine the current state of research both domestically and internationally, systematize cutting-edge findings and clinical challenges, thereby clarifying future research directions. Such efforts will better address practical clinical issues in neonatal pneumonia treatment and enable the translation of relevant research outcomes into clinical practice protocols.

## **Funding**

No

## **Conflict of Interests**

The authors declare that there is no conflict of interest regarding the publication of this paper.

## Reference

- [1] Yang, X. (2025). Clinical value of combined acetylcysteine and budesonide nebulization therapy in neonatal pneumonia. Chinese Science & Technology Journal Database (Abstract Edition): Medicine & Health, (5), 037–040.
- [2] Chen, H. R. (2025). Effect of cefotaxime injection combined with ambroxol injection and budesonide nebulization on neonatal pneumonia and its impact on inflammatory factor levels. Chinese Science & Technology Journal Database: Medicine, (5), 029–032.
- [3] Jin, J. N., & Wu, X. Y. (2021). Analysis of the application value of antibiotics in treating neonatal pneumonia and their impact on recovery time. Systematic Medicine, 6(15), 89–91.
- [4] Sun, Z. C. (2021). Clinical application and time-effect analysis of antibiotics in the treatment of neonatal pneumonia. Smart Health, 7(7), 148–150.

**Dear Researchers and Scholars :**

Greetings from Asia Pacific Science Press, a beacon of academic and scientific publishing, located in the vibrant city of Hong Kong.

We extend our heartfelt gratitude for your relentless pursuit of knowledge, and your significant contributions to the advancement of science and society. It is researchers and scholars like you who propel humanity forward, and we at the Asia Pacific Science Press are devoted to ensuring that your groundbreaking works receive the global recognition they rightfully deserve.

In light of our commitment to disseminating pioneering research across various disciplines, such as medicine, architecture, education, and electronics, we are reaching out with two pivotal opportunities to augment our collaboration with the global academic community:

**Call for Paper Submissions:**

We cordially invite you to submit your original research articles to our fast-growing, peer-reviewed, and open-access journals. Our platform guarantees an extensive, global reach, enabling your work to garner maximum visibility and citation in the academic sphere. Rest assured, your work will be meticulously assessed by experts in the field, ensuring it receives the acknowledgment and exposure it merits.

**Join Our Esteemed Team:**

We are fervently searching for passionate researchers and scholars interested in joining our burgeoning team at Asia Pacific Science Press. We offer numerous roles, such as peer reviewers, editors, and advisory board members, where your expertise will significantly shape the content and quality of our publications. In return, you will gain invaluable experience, network with preeminent scholars, and play a pivotal role in molding the future of global academic publishing.

**Why Choose Asia Pacific Science Press?**

**Global Reach:** Your work will be accessible to a worldwide audience, free from any access barriers.

**Collaboration with Renowned Universities:** We have established extensive publishing systems in cooperation with world-renowned universities, such as Wuhan University, Hong Kong University, and the University of Malaya.

**Diverse Disciplines:** Your research will be housed among numerous journals across a multitude of academic projects and disciplines.

As we stride forward in the academic landscape, we envision a future where our collective efforts shape a more enlightened, innovative, and interconnected global society. We sincerely hope that you consider this invitation to join us on this auspicious journey towards knowledge, discovery, and global impact.

Should you wish to submit your work or express interest in joining our team, please do not hesitate to contact us. You can submit your manuscript or personal profile to [info@apspublisher.com](mailto:info@apspublisher.com) or visit our website at [www.apspublisher.com](http://www.apspublisher.com) for more information.

Thank you for considering this opportunity, and we eagerly anticipate the possibility of welcoming you to the Asia Pacific Science Press family. Together, let's forge a future of unparalleled scientific advancement and discovery.

Warm regards  
Asia Pacific Science Press



## OUR JOURNALS

**Asia Pacific Economic and Management Review** is an international, peer-reviewed and open access journal which focuses on theoretical and applied studies of corporate and financial behavior. Aiming to promote the research in fields of business economics and management, it covers mainly but not limits to the following areas: accounting and financial management, economics, human resource management and organizational behavior, information management, international business, strategy and innovation, management science and operations management, marketing and retailing, finance.



**Critical Humanistic Social Theory** is an journal that publishes papers specifically using quantitative or qualitative research methods for social science research. The journal encourages scholars to conduct social science theory research from the perspective of social critical theory and emphasizes research concerned with issues or methods that cut across traditional disciplinary lines.



**Journal of Educational Theory and Practice** is an international, peer-reviewed and open access journal which is to promote the evaluative, integrative, theoretical and methodological research on contemporary education; shape a novel, broader view of issues in contemporary education; enhance the caliber of humanities research through active use of best domestic and foreign practices; and integrate the achievements of various sciences and knowledge areas with unconventional approaches.



**Journal of Advances in Engineering and Technology** is an international, peer-reviewed and open access journal which publishes original articles, reviews, short communications, case studies and letters in the field of electronic research and application.





**Advances in Management and Intelligent Technologies** is an international, peer-reviewed, open-access academic journal, hosted by the Fujian Strait Institute of Intelligent Equipment and managed and published by Asia-Pacific Science Press. It focuses on the latest research in the fields of management and intelligent technologies, and aims to advance both theoretical and applied research in management, technological innovation, and intelligent development.



**Asia Pacific Journal of Clinical Medical Research** is an international, peer-reviewed, open access journal dedicated to advancing clinical medical research across multiple disciplines. The journal serves as a platform for publishing high-quality original research, reviews, and clinical studies that enhance the understanding of medical practices, treatment innovations, and healthcare outcomes, thereby supporting patient care and medical advancements in the Asia Pacific region and beyond.



**Asia Pacific Journal of Educational Research** is an international, peer-reviewed, open-access academic journal focusing on educational theory and practice. It publishes high-quality research on educational reform, teaching methods, educational equity, and policy studies. The journal addresses practical needs and institutional changes in the education systems of the Asia-Pacific region, advocating a balance between theoretical inquiry and practical experience. It encourages original studies from multicultural, comparative, and interdisciplinary perspectives, aiming to support educational innovation and policy development across the region.



**Asia Pacific Economic and Social Development** is an international, peer-reviewed, open-access academic journal openly distributed to the global academic community. The journal is committed to publishing original research with theoretical depth and practical value in the fields of economic and social development. It focuses on issues such as economic behavior, social structure transformation, policy innovation, and regional coordinated development in the Asia-Pacific region. The journal encourages interdisciplinary perspectives and promotes the integration of economics, sociology, management, and related disciplines.

